@article{fdi:010055837,
  title = {{R}educed quantitative ultrasound bone mineral density in hiv-infected patients on antiretroviral therapy in {S}enegal},
  author = {{C}ournil, {A}mandine and {E}ymard-{D}uvernay, {S}abrina and {D}iouf, {A}. and {M}oquet, {C}. and {C}outherut, {J}ulie and {N}gom {G}ueye, {N}. {F}. and {C}ames, {C}{\'e}cile and {T}averne, {B}ernard and {B}ork, {K}irsten and {S}ow, {P}. {S}. and {D}elaporte, {E}ric},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground: {B}one status in {HIV}-infected patients on antiretroviral treatment ({ART}) is poorly documented in resource-limited settings. {W}e compared bone mineral density between {HIV}-infected patients and control subjects from {D}akar, {S}enegal. {M}ethods: {A} total of 207 (134 women and 73 men) {HIV}-infected patients from an observational cohort in {D}akar ({ANRS} 1215) and 207 age-and sex-matched controls from the general population were enrolled. {B}one mineral density was assessed by quantitative ultrasound ({QUS}) at the calcaneus, an alternative to the reference method (i.e. dual {X}-absorptiometry), often not available in resource-limited countries. {R}esults: {M}ean age was 47.0 (+/- 8.5) years. {P}atients had received {ART} for a median duration of 8.8 years; 45% received a protease inhibitor and 27% tenofovir; 84% had undetectable viral load. {P}atients had lower body mass index ({BMI}) than controls (23 versus 26 kg/m(2), {P}<0.001). {I}n unadjusted analysis, {QUS} bone mineral density was lower in {HIV}-infected patients than in controls (difference: -0.36 standard deviation, 95% confidence interval ({CI}): -0.59;-0.12, {P} = 0.003). {A}djusting for {BMI}, physical activity, smoking and calcium intake attenuated the difference (-0.27, {CI}: -0.53; -0.002, {P} = 0.05). {D}ifferences in {BMI} between patients and controls explained a third of the difference in {QUS} bone mineral density. {A}mong patients, {BMI} was independently associated with {QUS} bone mineral density ({P}<0.001). {A}n association between undetectable viral load and {QUS} bone density was also suggested (beta = 0.48, {CI}: 0.02; 0.93; {P} = 0.04). {N}o association between protease inhibitor or tenofovir use and {QUS} bone mineral density was found. {C}onclusion: {S}enegalese {HIV}-infected patients had reduced {QUS} bone mineral density in comparison with control subjects, in part related to their lower {BMI}. {F}urther investigation is needed to clarify the clinical significance of these observations.},
  keywords = {},
  booktitle = {},
  journal = {{P}los {O}ne},
  volume = {7},
  numero = {2},
  pages = {e31726},
  ISSN = {1932-6203},
  year = {2012},
  DOI = {10.1371/journal.pone.0031726},
  URL = {https://www.documentation.ird.fr/hor/fdi:010055837},
}